Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence

Abstract

Recurrent or persistent inflammation has emerged as an important factor in cancer development. Overexpression of macrophage migration inhibitory factor (MIF), an upstream regulator of innate immunity with pleiotropic effects on cell proliferation, has been implicated in prostate cancer (CaP). Two polymorphisms in the promoter of the MIF gene (−173G to C transition and seven copies of the −794 CATT repeat) are associated with increased MIF expression in vivo and poor prognosis in autoimmune diseases. We conducted a retrospective analysis of 131 CaP patients and 128 controls from a group of Veterans' Administration patients undergoing routine prostate-specific antigen screening. Patients with CaP were enrolled regardless of treatment. Inclusion criteria for the control group were absence of documented diagnosis of cancer and/or chronic inflammation within patient computerized records. Logistic regression demonstrated a significant association between CaP and the −173G/C, the −173C/C and the −794 7-CATT MIF polymorphisms (P<0.001). Patients with the −794 7-CATT allele had an increased risk of CaP recurrence at 5 years. Individuals with −173G/C, −173C/C and −794 7-CATT MIF genotypes have an increased incidence of CaP and these genotypes may serve as an independent marker for cancer recurrence.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Cancer Facts & Figures 2007. In: http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf. American Cancer Society, 2007.

  2. George NJ . Conservative management of prostate cancer. Lancet 1988; 1: 1001–1010.

    Article  CAS  Google Scholar 

  3. Hamdy FC . Prognostic and predictive factors in prostate cancer. Cancer Treat Rev 2001; 27: 143–151.

    Article  CAS  Google Scholar 

  4. Debes JD, Tindall DJ . Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004; 351: 1488–1490.

    Article  CAS  Google Scholar 

  5. Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, Sanjo H et al. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 2006; 124: 615–629.

    Article  CAS  Google Scholar 

  6. Coussens LM, Werb Z . Inflammation and cancer. Nature 2002; 420: 860–867.

    Article  CAS  Google Scholar 

  7. Cordon-Cardo C, Prives C . At the crossroads of inflammation and tumorigenesis. J Exp Med 1999; 190: 1367–1370.

    Article  CAS  Google Scholar 

  8. Karin M, Lawrence T, Nizet V . Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006; 124: 823–835.

    Article  CAS  Google Scholar 

  9. De Marzo AM, Marchi VL, Epstein JI, Nelson WG . Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999; 155: 1985–1992.

    Article  CAS  Google Scholar 

  10. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2005; 26: 1170–1181.

    Article  CAS  Google Scholar 

  11. Mahmud S, Franco E, Aprikian A . Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 2004; 90: 93–99.

    Article  CAS  Google Scholar 

  12. Platz EA, Rohrmann S, Pearson JD, Corrada MM, Watson DJ, De Marzo AM et al. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev 2005; 14: 390–396.

    Article  CAS  Google Scholar 

  13. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7: 256–269.

    Article  CAS  Google Scholar 

  14. Mitchell RA, Bucala R . Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Semin Cancer Biol 2000; 10: 359–366.

    Article  CAS  Google Scholar 

  15. Chesney J, Metz C, Bacher M, Peng T, Meinhardt A, Bucala R . An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med 1999; 5: 181–191.

    Article  CAS  Google Scholar 

  16. Mitchell RA, Metz CN, Peng T, Bucala R . Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 1999; 274: 18100–18106.

    Article  CAS  Google Scholar 

  17. Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH . A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 1999; 190: 1375–1382.

    Article  CAS  Google Scholar 

  18. Bando H, Matsumoto G, Bando M, Muta M, Ogawa T, Funata N . Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread. Jpn J Cancer Res 2002; 93: 389–396.

    Article  CAS  Google Scholar 

  19. Bini L, Magi B, Marzocchi B, Arcuri F, Tripodi S, Cintorino M et al. Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis 1997; 18: 2832–2841.

    Article  CAS  Google Scholar 

  20. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K et al. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 2005; 175: 1197–1205.

    Article  CAS  Google Scholar 

  21. Yao K, Shida S, Selvakumaran M, Zimmerman R, Simon E, Schick J et al. Macrophage migration inhibitory factor is a determinant of hypoxia-induced apoptosis in colon cancer cell lines. Clin Cancer Res 2005; 11: 7264–7272.

    Article  CAS  Google Scholar 

  22. Legendre H, Decaestecker C, Nagy N, Hendlisz A, Schüring MP, Salmon I et al. Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers. Mod Pathol 2003; 16: 491–504.

    Article  Google Scholar 

  23. White ES, Flaherty KR, Carskadon S, Brant A, Iannettoni MD, Yee J et al. Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res 2003; 9: 853–860.

    CAS  PubMed  Google Scholar 

  24. Tomiyasu M, Yoshino I, Suemitsu R, Okamoto T, Sugimachi K . Quantification of macrophage migration inhibitory factor mRNA expression in non-small cell lung cancer tissues and its clinical significance. Clin Cancer Res 2002; 8: 3755–3760.

    CAS  PubMed  Google Scholar 

  25. Meyer-Siegler K, Fattor RA, Hudson PB . Expression of macrophage migration inhibitory factor in the human prostate. Diagn Mol Pathol 1998; 7: 44–50.

    Article  CAS  Google Scholar 

  26. Meyer-Siegler KL, Iczkowski KA, Vera PL . Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer. BMC Cancer 2005; 5: 73.

    Article  Google Scholar 

  27. Yu DS, Hsieh DS, Chang SY . Increasing expression of GST-pi MIF, and ID1 genes in chemoresistant prostate cancer cells. Arch Androl 2006; 52: 275–281.

    Article  CAS  Google Scholar 

  28. Baugh JA, Chitnis S, Donnelly SC, Monteiro J, Lin X, Plant BJ et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun 2002; 3: 170–176.

    Article  CAS  Google Scholar 

  29. Donn RP, Shelley E, Ollier WE, Thomson W, British Paediatric Rheumatology Study Group. A novel 5′-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2001; 44: 1782–1785.

    Article  CAS  Google Scholar 

  30. Barton A, Lamb R, Symmons D, Silman A, Thomson W, Worthington J et al. Macrophage migration inhibitory factor (MIF) gene polymorphism is associated with susceptibility to but not severity of inflammatory polyarthritis. Genes Immun 2003; 4: 487–491.

    Article  CAS  Google Scholar 

  31. Zhong XB, Leng L, Beitin A, Chen R, McDonald C, Hsiao B et al. Simultaneous detection of microsatellite repeats and SNPs in the macrophage migration inhibitory factor (MIF) gene by thin-film biosensor chips and application to rural field studies. Nucleic Acids Res 2005; 33: e121.

    Article  Google Scholar 

  32. Wu S-P, Leng L, Feng Z, Liu N, Zhao H, McDonald C et al. Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. Arthritis Rheum 2006; 54: 3661–3669.

    Article  CAS  Google Scholar 

  33. Stephens M, Scheet P . Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 2005; 76: 449–462.

    Article  CAS  Google Scholar 

  34. Meyer-Siegler KL, Bellino MA, Tannenbaum M . Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer 2002; 94: 1449–1456.

    Article  CAS  Google Scholar 

  35. Coughlin SS, Hall IJ . A review of genetic polymorphisms and prostate cancer risk. Ann Epidemiol 2002; 12: 182–196.

    Article  Google Scholar 

  36. Wu HC, Chang CH, Chen HY, Tsai FJ, Tsai JJ, Chen WC . p53 gene codon 72 polymorphism but not tumor necrosis factor-alpha gene is associated with prostate cancer. Urol Int 2004; 73: 41–46.

    Article  CAS  Google Scholar 

  37. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 2002; 62: 3369–3372.

    CAS  PubMed  Google Scholar 

  38. Michaud DS, Daugherty SE, Berndt SI, Platz EA, Yeager M, Crawford ED et al. Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res 2006; 66: 4525–4530.

    Article  CAS  Google Scholar 

  39. Lindmark F, Zheng SL, Wiklund F, Bensen J, Bälter KA, Chang B et al. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. J Natl Cancer Inst 2004; 96: 1248–1254.

    Article  CAS  Google Scholar 

  40. Hayes VM, Severi G, Southey MC, Padilla EJ, English DR, Hopper JL et al. Macrophage inhibitory cytokine-1 H6D polymorphism, prostate cancer risk, and survival. Cancer Epidemiol Biomarkers Prev 2006; 15: 1223–1225.

    Article  CAS  Google Scholar 

  41. Fingerle-Rowson G, Petrenko O, Metz CN, Forsthuber TG, Mitchell R, Huss R et al. The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci USA 2003; 100: 9354–9359.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was funded by grants from VA Merit Review Program (KLMS, PLV), the NIH (1R21DK075059-01-A1, PLV; R01AR050498 RB), Donaghue Foundation and the Yale Department of Pathology (CB).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to K L Meyer-Siegler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meyer-Siegler, K., Vera, P., Iczkowski, K. et al. Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence. Genes Immun 8, 646–652 (2007). https://doi.org/10.1038/sj.gene.6364427

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gene.6364427

Keywords

This article is cited by

Search

Quick links